![Richard Marshak](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Richard Marshak
Corporate Officer/Principal en TRISALUS LIFE SCIENCES, INC. .
Fortuna: 195 117 $ al 31/05/2024
Cargos activos de Richard Marshak
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TRISALUS LIFE SCIENCES, INC. | Corporate Officer/Principal | 10/08/2023 | - |
Nephraegis Therapeutics, Inc.
![]() Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Director/Miembro de la Junta | 01/09/2018 | - |
Fundador | 01/09/2018 | - | |
Corporate Officer/Principal | 01/09/2018 | - |
Historial de carrera de Richard Marshak
Antiguos cargos conocidos de Richard Marshak.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
LF Consulting
![]() LF Consulting Miscellaneous Commercial ServicesCommercial Services LF Consulting specializes in data management and analysis. The private company is based in Sherwood, OR. The company's services include obtaining, transforming, processing, and visualizing data to help clients make informed decisions. | Presidente | 01/01/2013 | 01/06/2022 |
Mount TAM Biotechnologies, Inc.
![]() Mount TAM Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P. Aldridge in November 2011 and is headquartered in Burlington, VT. | Director/Miembro de la Junta | 01/03/2016 | 01/10/2019 |
Director Ejecutivo | 01/03/2016 | 01/10/2019 | |
ABBOTT LABORATORIES | Corporate Officer/Principal | 01/01/1999 | 01/01/2013 |
Formación de Richard Marshak.
University of Pennsylvania | Undergraduate Degree |
The University of Chicago Booth School of Business | Masters Business Admin |
Estadísticas
Internacional
Estados Unidos | 8 |
Operativa
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
TRISALUS LIFE SCIENCES, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Mount TAM Biotechnologies, Inc.
![]() Mount TAM Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Mount TAM Biotechnologies, Inc. is a biopharmaceutical company, which engages in the development of therapeutic products for targeting systemic lupus erythematosus ("SLE"). It also focuses in the discovery and development of novel mTOR inhibitors, with specific emphasis on developing compounds with unique mTORC1:mTORC2 inhibitory profiles. The company was founded by Chester P. Aldridge in November 2011 and is headquartered in Burlington, VT. | Health Technology |
LF Consulting
![]() LF Consulting Miscellaneous Commercial ServicesCommercial Services LF Consulting specializes in data management and analysis. The private company is based in Sherwood, OR. The company's services include obtaining, transforming, processing, and visualizing data to help clients make informed decisions. | Commercial Services |
Nephraegis Therapeutics, Inc.
![]() Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Health Technology |
- Bolsa de valores
- Insiders
- Richard Marshak
- Experiencia